James Abbruzzese, MD

Professor of Medicine
D. C. I. Professor of Medical Oncology
Chief, Division of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., University of Chicago, 1978

Publications

Beran, M., H. Kantarjian, S. O’Brien, C. Koller, M. al-Bitar, S. Arbuck, S. Pierce, et al. “Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia..” Blood 88, no. 7 (October 1, 1996): 2473–79.

PMID
8839838
Scholars@Duke

Abbruzzese, J. L. “Phase I studies with the novel nucleoside analog gemcitabine..” Semin Oncol 23, no. 5 Suppl 10 (October 1996): 25–31.

PMID
8893878
Scholars@Duke

Abbruzzese, J. L., T. Madden, S. M. Sugarman, A. L. Ellis, S. Loughlin, K. R. Hess, R. A. Newman, L. A. Zwelling, and M. N. Raber. “Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor..” Clin Cancer Res 2, no. 9 (September 1996): 1489–97.

PMID
9816325
Scholars@Duke

Rothenberg, M. L., J. L. Abbruzzese, M. Moore, R. K. Portenoy, J. M. Robertson, and H. J. Wanebo. “A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma..” Cancer 78, no. 3 Suppl (August 1, 1996): 627–32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y.

PMID
8681301
Full Text

Staley, C. A., K. R. Cleary, J. L. Abbruzzese, J. E. Lee, F. C. Ames, C. J. Fenoglio, and D. B. Evans. “The need for standardized pathologic staging of pancreaticoduodenectomy specimens..” Pancreas 12, no. 4 (May 1996): 373–80.

PMID
8740405
Scholars@Duke

Abbruzzese, J. L., M. C. Abbruzzese, R. Lenzi, M. N. Raber, and K. R. Hess. “Are time or intensity factors important to the definition of metastases of unknown origin?.” J Natl Cancer Inst 88, no. 7 (April 3, 1996): 462–63. https://doi.org/10.1093/jnci/88.7.462-a.

PMID
8618241
Full Text

Frazier, M. L., E. Fernández, R. de Llorens, N. M. Brown, S. Pathak, K. R. Cleary, J. L. Abbruzzese, et al. “Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells..” Int J Pancreatol 19, no. 1 (February 1996): 31–38. https://doi.org/10.1007/BF02788373.

PMID
8656025
Full Text

Staley, C. A., J. E. Lee, K. R. Cleary, J. L. Abbruzzese, C. J. Fenoglio, T. A. Rich, and D. B. Evans. “Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head..” Am J Surg 171, no. 1 (January 1996): 118–24. https://doi.org/10.1016/S0002-9610(99)80085-3.

PMID
8554125
Full Text

Pazdur, R., N. J. Meropol, E. S. Casper, C. Fuchs, H. O. Douglass, M. Vincent, and J. L. Abbruzzese. “Phase II trial of ZD1694 (Tomudex) in patients with advanced pancreatic cancer..” Invest New Drugs 13, no. 4 (1996): 355–58.

PMID
8824356
Scholars@Duke

Abbruzzese, J. L. “Phase I studies with the novel nucleoside analog gemcitabine.” Seminars in Oncology 23, no. 5 SUPPL. 10 (1996): 25–31.

Scholars@Duke

Pages